• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在初级预防失败后,立即进行抢救性婴儿花生口服免疫治疗是合理的。

The Case for Prompt Salvage Infant Peanut Oral Immunotherapy Following Failed Primary Prevention.

机构信息

Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China; Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong SAR, China; Department of Paediatrics, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Section of Allergy and Clinical Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.

出版信息

J Allergy Clin Immunol Pract. 2022 Oct;10(10):2561-2569. doi: 10.1016/j.jaip.2022.05.040. Epub 2022 Jun 23.

DOI:10.1016/j.jaip.2022.05.040
PMID:35752433
Abstract

Recent guideline recommendations have shifted from recommending prolonged avoidance of allergenic foods in the first 3 years of life to a primary prevention approach involving the deliberate early introduction to infants at risk of developing food allergy. Despite this, some infants, especially those with severe eczema who are at highest risk for developing peanut allergy, fail to receive the preventative benefits of early peanut introduction due to hesitancy and other factors. Difficulty adhering to regular ingestion after introduction further reduces the effectiveness of primary prevention. As emerging real-world evidence has demonstrated that performing peanut oral immunotherapy (OIT) among infants is effective and safe, peanut OIT could be a treatment option for infants with peanut allergy. This review discusses the benefits, risks, and barriers to offering peanut OIT to infants who fail primary prevention strategies. We propose the novel concept that infants with peanut allergy be offered peanut OIT as soon as possible after failed peanut introduction through a shared decision-making process with the family, where there is a preference for active management rather than avoidance.

摘要

最近的指南建议已经从推荐在生命的头 3 年中长时间避免食用致敏食物,转变为一种主要的预防方法,包括有针对性地早期向有食物过敏风险的婴儿引入。尽管如此,由于犹豫不决和其他因素,一些婴儿,尤其是那些患有严重湿疹的婴儿,他们面临着发展为花生过敏的最高风险,无法从早期引入花生中获得预防益处。在引入后难以坚持定期摄入,进一步降低了主要预防措施的效果。由于新出现的真实世界证据表明,在婴儿中进行花生口服免疫治疗(OIT)是有效和安全的,因此花生 OIT 可能成为花生过敏婴儿的一种治疗选择。这篇综述讨论了为未能通过主要预防策略的婴儿提供花生 OIT 的益处、风险和障碍。我们提出了一个新的概念,即一旦婴儿在引入花生后失败,应尽快通过与家庭的共同决策过程为其提供花生 OIT,因为家庭更倾向于积极管理而不是回避。

相似文献

1
The Case for Prompt Salvage Infant Peanut Oral Immunotherapy Following Failed Primary Prevention.在初级预防失败后,立即进行抢救性婴儿花生口服免疫治疗是合理的。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2561-2569. doi: 10.1016/j.jaip.2022.05.040. Epub 2022 Jun 23.
2
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.益生菌花生口服免疫治疗与口服免疫治疗和安慰剂在澳大利亚花生过敏儿童中的比较(PPOIT-003):一项多中心、随机、2b 期试验。
Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4.
3
Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age.早期花生免疫治疗(EPIC)试验:5 岁以下儿童花生口服免疫治疗的实用随机对照试验方案。
BMJ Paediatr Open. 2023 Nov;7(1). doi: 10.1136/bmjpo-2023-002294.
4
Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy.食物过敏免疫疗法:口服免疫疗法和经皮免疫疗法。
Allergy. 2020 Jun;75(6):1337-1346. doi: 10.1111/all.14220. Epub 2020 Feb 28.
5
[The clinical advances of the peanut oral immunotherapy].[花生口服免疫疗法的临床进展]
Zhonghua Yu Fang Yi Xue Za Zhi. 2021 May 6;55(5):592-597. doi: 10.3760/cma.j.cn112150-20210308-00226.
6
Food Allergy Prevention: More Than Peanut.食物过敏预防:不止于花生。
J Allergy Clin Immunol Pract. 2020 Jan;8(1):1-13. doi: 10.1016/j.jaip.2019.11.002.
7
Oral Immunotherapy: An Overview.口服免疫疗法概述
Prim Care. 2023 Jun;50(2):269-281. doi: 10.1016/j.pop.2022.11.006. Epub 2023 Feb 26.
8
Peanut Oral Immunotherapy With or Without H and H Antihistamine Premedication for Peanut Allergy (PISCES): A Placebo-Controlled Randomized Clinical Trial.花生口服免疫治疗联合或不联合 H 和 H 抗组胺药预处理治疗花生过敏(PISCES):一项安慰剂对照随机临床试验。
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2386-2394. doi: 10.1016/j.jaip.2022.05.015. Epub 2022 May 25.
9
Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).多中心、随机、对照试验研究方案,评估益生菌和花生口服免疫治疗(PPOIT)与单独口服免疫治疗(OIT)和安慰剂相比在诱导花生过敏儿童脱敏或耐受方面的有效性(PPOIT-003 研究)。
BMJ Open. 2020 Sep 9;10(9):e035871. doi: 10.1136/bmjopen-2019-035871.
10
Update on peanut allergy: Prevention and immunotherapy.花生过敏的最新进展:预防与免疫疗法。
Allergy Asthma Proc. 2019 Jan 1;40(1):14-20. doi: 10.2500/aap.2019.40.4190.

引用本文的文献

1
Emergency Monitoring Following A Diagnosis of Anaphylaxis.过敏反应诊断后的紧急监测
Curr Allergy Asthma Rep. 2025 Jul 8;25(1):29. doi: 10.1007/s11882-025-01210-z.
2
Oral Immunotherapy Should Play a Key Role in Preschool Food Allergy Management.口服免疫疗法应在学龄前儿童食物过敏管理中发挥关键作用。
Clin Exp Allergy. 2025 Apr;55(4):294-306. doi: 10.1111/cea.70013. Epub 2025 Mar 5.
3
Food oral immunotherapy.食物口服免疫疗法
Allergy Asthma Clin Immunol. 2025 Feb 12;20(Suppl 3):82. doi: 10.1186/s13223-025-00948-5.
4
Safety and adherence of early oral immunotherapy for peanut allergy in a primary care setting: a retrospective cross-sectional study.基层医疗环境中花生过敏早期口服免疫疗法的安全性与依从性:一项回顾性横断面研究
Allergy Asthma Clin Immunol. 2024 Oct 24;20(1):57. doi: 10.1186/s13223-024-00916-5.
5
Peanut Allergy in Children-Is Prevention Better than Cure?儿童花生过敏——预防胜于治疗?
Nutrients. 2024 Sep 25;16(19):3237. doi: 10.3390/nu16193237.
6
Safety and Feasibility of Peanut, Tree Nut, and Sesame Oral Immunotherapy in Infants and Toddlers in a Real-World Setting.现实环境中婴幼儿花生、坚果和芝麻口服免疫疗法的安全性和可行性
J Allergy Clin Immunol Pract. 2025 Jan;13(1):185-191.e3. doi: 10.1016/j.jaip.2024.09.025. Epub 2024 Sep 30.
7
Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study.奥马珠单抗的实际应用:来自 OUtMATCH 研究的经验教训。
J Allergy Clin Immunol Pract. 2024 Nov;12(11):2947-2954. doi: 10.1016/j.jaip.2024.08.056. Epub 2024 Sep 16.
8
Anaphylaxis: Definition and criteria.过敏反应:定义与标准。
J Food Allergy. 2024 Jul 1;6(1):26-31. doi: 10.2500/jfa.2024.6.240002. eCollection 2024 Jul.
9
Food allergy prevention through the decades: An ounce of humility is worth a pound of cure.数十年来的食物过敏预防:一盎司的谦逊抵得上一磅的治疗。
J Food Allergy. 2024 Jul 1;6(1):3-14. doi: 10.2500/jfa.2024.6.230018. eCollection 2024 Jul.
10
Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making.高危婴儿花生过敏的风险亚组和干预效果:临床决策模型。
Clin Exp Allergy. 2024 Mar;54(3):185-194. doi: 10.1111/cea.14452. Epub 2024 Jan 19.